Safety warnings you must pay attention to when using spesolimab-sbzo

Pesolimab (spesolimab-sbzo) is an innovative biologic designed to treat adults with generalized pustular psoriasis (GPP), a serious skin disease. GPP is a rare autoimmune disease. The patient's skin will suddenly appear with widespread erythema and sterile pustules, accompanied by severe pain, fever and other systemic symptoms, which seriously affects the patient's daily life. Pesolimab can effectively reduce the patient's inflammatory response by specifically inhibiting the IL-36 receptor signaling pathway, thereby improving skin symptoms. However, there are some important safety warnings that patients and healthcare professionals must heed when using pesolizumab to ensure the treatment is safe and effective.

First, patients with a history of hypersensitivity to pessolimab or any of its components should strictly avoid using this drug. Anaphylaxis may include severe symptoms such as difficulty breathing, laryngeal edema, hypotension, or shock. If this occurs, seek medical attention immediately.

Secondly, because pesolimab may affect the function of the immune system, this drug should be avoided when patients have active infections, such as tuberculosis, sepsis, etc. Use of pessolimab may increase the risk of infection, especially in patients with weakened immune systems. Therefore, patients should closely monitor their symptoms of infection during use and take appropriate preventive measures.

In addition, patients should avoid receiving live vaccines while receiving pesolizumab. Live vaccines may trigger an immune response, and pesolizumab may interfere with this response, making the vaccine less protective. Pregnant women, lactating women, the elderly, and patients with severe hepatic and renal insufficiency should be particularly cautious when using pesolizumab. These groups may need to adjust the dose or choose other treatment options.

In general, pesolizumab provides new treatment hope forGPP patients. However, during use, patients and medical staff must strictly abide by safety warnings and closely monitor the patient's response to ensure the safety and effectiveness of the treatment. Any abnormal symptoms or discomfort should be reported to the doctor in time for necessary treatment.

Reference materials：https://www.drugs.com/spevigo.html